Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … uncommon problems and critical about own work Passion for innovation and drive to deliver new therapies to patients …
… forms are recognized and valued. We offer an exciting and innovative working environment in a very committed … recruitment@proqr.com if you have any questions. Science & Innovation …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … forms are recognized and valued. We offer an exciting and innovative working environment in a very committed … recruitment@proqr.com if you have any questions. Science & Innovation …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … potential and developing an opportunity map for extending innovation horizons. We expect our Director Target Hunting …
… functions. Axiomer could potentially yield a new class of innovative medicines and treat currently untreatable … plan, including: Crafting detailed protocols Defining innovative endpoints Leading robust data analysis and … recruitment@proqr.com if you have any questions. Science & Innovation …
ProQR has announced the completion of an in-depth strategic review designed to deliver on our commitment to advance RNA therapies for diseases with high unmet need. We are also sharing additional analyses of the sepofarsen Illuminate trial.
2017 may become a very exciting year for Patricia Biasutto, sepofarsen captain. Her work, developing a novel RNA therapy for Leber congenital amaurosis 10, has progressed steadily. The team expects to start a first clinical trial this year.